Literature DB >> 3914173

[Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].

W Linkesch, H Gisslinger, H Ludwig, R Flener, H Sinzinger.   

Abstract

15 patients with myeloproliferative diseases and thrombocythaemia (7 Polycythaemia vera, 5 essential thrombocythaemia, 3 chronic myelogenous leukaemia) were assigned to a therapy with recombinant interferon (recombinant IFN-alpha-2C) in a prospective, controlled trial. Under therapy all patients showed a significant decrease in thrombocyte values. 51% of the patients revealed thrombocyte values within the normal range after 3 months of IFN therapy. Noted side effects of IFN therapy were dose-dependent and clinically well tolerated by the patients.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3914173

Source DB:  PubMed          Journal:  Acta Med Austriaca        ISSN： 0303-8173


  6 in total

Review 1.  New Therapeutic Approaches in Polycythemia Vera.

Authors:  Lorenzo Falchi; Kate J Newberry; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

2.  Interferon-alpha-2 in the treatment of idiopathic myelofibrosis.

Authors:  H L Seewann; G Gastl; A Lang; K Abbrederis; J Thaler; R Flener; C Huber
Journal:  Blut       Date:  1988-04

Review 3.  Treatment options and pregnancy management for patients with PV and ET.

Authors:  Yoko Edahiro
Journal:  Int J Hematol       Date:  2022-04-08       Impact factor: 2.490

4.  Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Authors:  Heinz Gisslinger; Oleh Zagrijtschuk; Veronika Buxhofer-Ausch; Josef Thaler; Ernst Schloegl; Guenther A Gastl; Dominik Wolf; Robert Kralovics; Bettina Gisslinger; Karin Strecker; Alexander Egle; Thomas Melchardt; Sonja Burgstaller; Ella Willenbacher; Martin Schalling; Nicole C Them; Pavla Kadlecova; Christoph Klade; Richard Greil
Journal:  Blood       Date:  2015-08-10       Impact factor: 22.113

Review 5.  Recent advances in prognostication and treatment of polycythemia vera.

Authors:  Bridget K Marcellino; Ronald Hoffman
Journal:  Fac Rev       Date:  2021-03-12

6.  Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?

Authors:  Richard T Silver
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.